Latest news
Eli Lilly Locks In Retatrutide FDA Filing Date — Can the Stock Climb to $1,750 by 2027? - nai500.comnai500.com · Sat, 08 Aug 2026 02:03:05 GMTEli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 22:50:00 GMTEli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 22:29:17 GMTEli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started? - AOL.comAOL.com · Fri, 07 Aug 2026 17:43:57 GMTEli Lilly offers new weight loss drug to some patients before FDA approval - LiveNOW from FOXLiveNOW from FOX · Fri, 07 Aug 2026 15:20:40 GMTSpotlight On: Lilly reiterates BLA route for next-gen obesity drug and expects to find common ground with FDA on filing plans - FirstWord PharmaFirstWord Pharma · Thu, 06 Aug 2026 14:31:57 GMTEli Lilly Q2: Strong Results Further Strengthen The Investment Thesis (NYSE:LLY) - Seeking AlphaSeeking Alpha · Thu, 06 Aug 2026 06:09:31 GMTLilly Expands Retatrutide Access Amid Doctor Pushback - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Wed, 05 Aug 2026 20:37:18 GMT